Protara Therapeutics Inc.

NASDAQ: TARA · Real-Time Price · USD
3.03
-0.16 (-5.02%)
At close: Aug 15, 2025, 3:59 PM
3.09
1.98%
After-hours: Aug 15, 2025, 07:48 PM EDT

Protara Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 332K n/a n/a n/a 1.21M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
98K 83K n/a 84K 83K 83K 107K 107K 420K 77K 74K 64K 395K 397K n/a n/a 55K 32K
Gross Profit
-98K -83K 166K -84K -83K -83K 1.1M -107K -420K -77K -74K -64K -395K -397K n/a n/a -55K -32K
Operating Income
-16.59M -14.12M -14.31M -12.33M -10.66M -11.85M -11.04M -10.7M -12.14M -9.73M 20.47M -7.97M -8.71M -10.87M -10.29M -10.83M -12.79M -13.58M
Interest Income
1.61M 1.72M 1.15M 1.1M 1.14M 747K 814K 840K 842K 687K 632K 557K 512K 529K 1.8M 547K 513K 397K
Pretax Income
-14.96M -11.91M -12.77M -11.22M -9.51M -11.1M -10.22M -9.86M -11.29M -9.04M -38.97M -7.69M -8.54M -10.76M -10.23M -10.78M -12.78M -13.46M
Net Income
-14.96M -11.91M -12.77M -11.22M -9.51M -11.1M -10.22M -9.86M -11.29M -8.36M -38.86M -7.41M -8.19M -10.64M -10.23M -10.78M -12.78M -13.46M
Selling & General & Admin
5.82M 4.98M 4.81M 4.26M 4.27M 4.1M 4.55M 4.48M 4.89M 4.59M 5M 4.51M 5.62M 5.61M 6.22M 6.74M 6.91M 6.54M
Research & Development
10.77M 9.15M 9.5M 8.07M 6.39M 7.67M 6.38M 6.22M 7.25M 5.14M 4.99M 3.47M 3.08M 5.27M 4.07M 4.09M 5.89M 7.04M
Other Expenses
n/a n/a n/a n/a n/a n/a 107K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
16.59M 14.12M 14.31M 12.33M 10.66M 11.77M 11.04M 10.7M 12.14M 9.73M 9.99M 7.97M 8.71M 10.87M 10.29M 10.83M 12.79M 13.58M
Interest Expense
1.63M n/a n/a n/a n/a n/a n/a n/a n/a n/a 107K 274K 346K 410K n/a 494K 503K 282K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a -107K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
16.59M 14.12M 14.31M 12.33M 10.66M 11.85M 11.04M 10.7M 12.14M 9.73M 9.99M 7.97M 8.71M 10.87M 10.29M 10.83M 12.79M 13.58M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a -687K -107K -283K -346K -119K n/a 24K n/a n/a
Shares Outstanding (Basic)
42.27M 40.71M 26.43M 22.33M 21.23M 11.42M 11.36M 11.35M 11.31M 11.3M 11.27M 11.27M 11.26M 11.25M 11.24M 11.24M 11.23M 11.23M
Shares Outstanding (Diluted)
42.27M 40.71M 26.43M 22.33M 21.23M 11.42M 11.36M 11.35M 11.31M 11.3M 11.27M 11.27M 11.26M 11.25M 11.24M 11.24M 11.23M 11.23M
EPS (Basic)
-0.35 -0.29 -0.48 -0.5 -0.45 -0.97 -0.9 -0.87 -1 -0.74 -3.45 -0.66 -0.73 -0.95 -0.91 -0.96 -1.14 -1.2
EPS (Diluted)
-0.35 -0.29 -0.48 -0.5 -0.45 -0.97 -0.9 -0.87 -1 -0.74 -3.45 -0.66 -0.73 -0.95 -0.91 -0.96 -1.14 -1.2
EBITDA
-16.59M -14.12M -14.23M -12.25M -10.58M -11.77M -10.93M -10.62M -12.06M -9.65M -38.79M -7.35M -7.8M -10.36M -10.23M -10.78M -12.73M -13.43M
EBIT
-14.96M -11.91M -14.31M -12.33M -10.66M -11.85M -11.04M -10.7M -12.14M -9.73M -38.86M -7.42M -8.19M -10.35M -10.23M -10.28M -12.28M -13.46M
Depreciation & Amortization
n/a 83K 82K 84K 83K 83K 107K 107K 420K 77K 74K 64K 395K 397K 54K 688K 55K 32K